1. Most Discussed
  2. Gainers & Losers
  1. Members, Techs apologise for the loss of thread titles, and are currently working on restoring them. They will be back asap. Thank you
PBT 4.6¢


  1. m123456

    1,250 Posts.
    The truth is, the falling SP currently is reflective of PBT2 being the last bastion of hope for Prana - and it being a dying light at that - when its moving into phase 3 in HD, with AD likely to follow and its just one of many compounds in the pipeline with human trials commencing this year on PBT434.. This next compound will not only target PD but many diseases associated with movement disorders, with a possible end game being both PBT2 and PBT434 being used in conjunction to treat both cognition and movement disabilities associated with neuro degenerative conditions.

    Kad posted this elsewhere on YMB a couple of days ago..
    The Parkinson's drug
    Very impressive animal testing this time by the independent Leeds University team. Due in clinic 2015.
    From the report:
    "While this financial year began with much attention focused on trial results for PBT2, one of our other development products also received an important boost when Parkinson’s UK awarded £150,000 to the University of Leeds to study the mechanism of PBT434. In three different animal models of Parkinson’s Disease, PBT434 has proven effective in preventing neuronal loss and preserving motor function, and we continue to develop the drug as one compound in a library of more than 1000 Metal Protein Attenuating Compounds (MPACs). " and
    "Prana’s lead development compound for movement disorders, PBT434, has been shown to prevent the aggregation of a key protein, alpha synuclein, implicated in the pathology of Parkinson’s Disease (PD) and other movement disorders such as Multiple System Atrophy. These findings together with the demonstration that PBT434 can preserve the neurons that perish in PD, were presented at the 17th Movement Disorders Congress of Parkinson’s Disease and Movement Disorders in Sydney in June 2013. Research into the potential disease modifying mechanisms of the drug has been assisted by the award of £150,000 grant from Parkinson’s UK to The University of Leeds to study PBT434 in collaboration with Melbourne’s Florey Institute of Neuroscience and Mental Health. Development of the drug has progressed into longer term toxicology studies and GMP manufacture of the drug to enable first in man studies in 2015."
    At this price strong buy does not go far enough

Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.